期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

干扰素治疗慢性髓细胞白血病的研究进展 被引量：3

原文传递
导出
摘要 BCR-ABL融合基因是慢性髓细胞白血病（CML）的标志性改变之一.CML的自然病程分为慢性期、加速期和急变期.酪氨酸激酶抑制剂（TKI）取代干扰素（IFN）和造血干细胞移植（HSCT）,成为CML的一线治疗方案.但TKI治疗CML,患者产生耐药性,慢性不良反应多,且无法完全清楚CML干细胞的存在对CML治疗的影响等问题愈来愈突出.而IFN作用于CML干细胞或TKI治疗缓解后以IFN维持治疗,可能为CML患者带来显著的远期治疗效果.笔者拟就近年IFN治疗CML的研究进展进行综述如下.
作者 王玲玲 姜扬文
机构地区 扬州大学医学院 江苏省苏北人民医院血液科
出处 《国际输血及血液学杂志》 CAS 2014年第2期151-154,共4页 International Journal of Blood Transfusion and Hematology
关键词 白血病 髓系 慢性 BCR-ABL阳性 干扰素 酪氨酸激酶抑制剂 联合治疗 细胞遗传学缓解
分类号 R733.72 [医药卫生—肿瘤]
  • 相关文献

参考文献30

  • 1H6glund M, Sandin F, Hellstr6m K, et al. Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry [J]. Blood, 2013, 122(7) :1284-1292.
  • 2Nasr R, Bazarbachi A. Chronic myeloid leukemia: "archetype"of the impact of targeted therapies[J]. Pathol Biol, 2012, 60 (4) :239-245.
  • 3Hughes TP, Hochhaus A, Branford S, et al. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and ST1571 (IRIS) [J]. Blood,2010,116 (19).. 3758-3765.
  • 4Castagnetti F, Palandri F, Amabile M, et al. Results of high- dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party[J]. Blood,2009,113(15) :3428- 3434.
  • 5Assouline S, Lipton JH. Monitoring response and resistance to treatment in chronic myeloid leukemia[J]. Curt Oncol, 2011,18 (2):71-83.
  • 6MOiler MC,Cortes JE, Kim DW, et al. Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations[J]. Blood, 2009, 114(24) :4944-4953.
  • 7Rosti G, Palandri F, Castagnetti F, et al. Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia[J]. Blood, 2009,114(24) :4933-4938.
  • 8Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia[J]. N Engl J Med,2010,362(24) :2251-2259.
  • 9Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia[J]. N EnglJ Med,2010,362 (24): 2260-2270.
  • 10Cortes JE, Kim DW, Kantarjian M, et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial[J]. J Clin Oncol, 2012,30 (28) :3486-3492.

二级参考文献17

  • 1Heisterkamp N, Starn K, GroffenJ, et al. Structural organization of the bcr gene and its role in the Ph' translocation. Nature, 1985,315: 758-761.
  • 2RowleyJD. Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluo.rescence and Giemsa staining. Nature, 1973,243: 290-293.
  • 3Hehlmann R,Hochhaus A,Baccarani M. Chronic myeloid leu.kaemia. Lancet, 2007 ,370:342-350.
  • 4Hehlmann R, Lauseker M,Jung-Munkwitz S, et al. Tolerability.adapted imatinib 800 mgld versus 400 mg/d versus 400 mgld plus interferon-a in newly diagnosed chronic myeloid leukemia.J Clin Oncol,2011,29: 1634-1642.
  • 5Palandri F , Castagnetti F , Iacobucci I, et al. The response to ima.tinib and interferon-alpha is more rapid than the response to ima.tinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase. Hae.matologica, 2010,95: 1415-1419.
  • 6Preudhomme C, GuilhotJ, Nicolini FE, et al. Imatinib plus pe.ginterferon alfa-2a in chronic myeloid leukemia. N EnglJ Med , 2010,363: 2511-2521.
  • 7Simonsson B, Gedde- Dahl T, Markevarn B, et al. Combination of pegylated IFN- a2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia. Blood, 2011,118: 3228-3235.
  • 8Verma D, Kantarjian H, ShanJ, et al. Sustained complete molecular response to imatinib in chronic myeloid leukemia: A target worth aiming and achieving. Blood, 2009, 114: Abstract 505.
  • 9Branford S, SeymourJF, Grigg A, et al. BCR - ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first- line treated patients have stable undetectable BCR-ABL using strict sensitivity crite.ria. Clin Cancer Res, 2007 ,13: 7080-7085.
  • 10Graham SM,Jergensen HG, Allan E, et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic my.eloid leukemia are insensitive to STI571 in vitro. Blood, 2002, 99: 319-325.

共引文献6

同被引文献23

  • 1刘利,刘强,郝淼旺,陈任安,蒋姗姗,张继良,王黎红,何华,吴绒丽,杜娟,叶盛开,尹单单,梁英民.非清髓单倍体造血干细胞移植联合格列卫治疗慢性粒细胞白血病[J].临床血液学杂志,2006,19(1):3-6. 被引量：10
  • 2干定云,陈燕.慢性粒细胞白血病分子靶向治疗的新进展[J].临床血液学杂志,2006,19(3):190-192. 被引量：20
  • 3肖志坚,钱林生.慢性粒细胞白血病的治疗进展[J].继续医学教育,2006,20(4):80-85. 被引量：7
  • 4Corbin, Amie S,Agarwal, Anupriya,Loriaux, Marc,Cortes, Jorge,Deininger, Michael W,Druker, Brian J.Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity[J]. Journal of Clinical Investigation . 2011 (1)
  • 5Druker Brian J,Guilhot Fran?ois,O’Brien Stephen G,Gathmann Insa,Kantarjian Hagop,Gattermann Norbert,Deininger Michael W N,Silver Richard T,Goldman John M,Stone Richard M,Cervantes Francisco,Hochhaus Andreas,Powell Bayard L,Gabrilove Janice L.Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. The New England Quarterly . 2006
  • 6Dino Veneri,Cristina Tecchio,Giovanna De Matteis.Long-term persistence of molecular response after discontinuation of interferon-alpha in two patients with chronic myeloid leukaemia. BLOOD TRANSFUSION . 2012
  • 7Deininger M W,Goldman J M,Melo J V.The molecular biology of chronic myeloid leukemia. Blood . 2000
  • 8Neil P. Shah,Chris Tran,Francis Y. Lee,Ping Chen,Derek Norris,Charles L. Sawye.Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor. Science . 2004
  • 9Greg R.Angstreich,WilliamMatsui,Carol AnnHuff,Milada S.Vala,JamesBarber,Anita L.Hawkins,Constance A.Griffin,B.Douglas Smith,Richard J.Jones.??Effects of imatinib and interferon on primitive chronic myeloid leukaemia progenitors(J)British Journal of Haematology . 2005 (3)
  • 10Martin H?glund,Fredrik Sandin,Karin Hellstr?m,Mats Bj?reman,Magnus Bj?rkholm,Mats Brune,Arta Dreimane,Marja Ekblom,S?ren Lehmann,Per Ljungman,Claes Malm,Berit Markev?rn,Kristina Myhr-Eriksson,Lotta Ohm,Ulla Olsson-Str?mberg,Anders Sj?lander,Hans Wadenvik,Bengt Simonsson,Leif Stenke,Johan Richter.??Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry(J)Blood . 2013 (7)

引证文献3

二级引证文献9

国际输血及血液学杂志
2014年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部